Grifols USA, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$9.3Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
24,074clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Xembify $1.8M associated (2023-2025)
- Prolastin-C Liquid $1.7M associated (2023-2025)
- Gamunex-C $1.0M associated (2023-2025)
- Hyperrab $384K associated (2023-2025)
- Thrombate III $68K associated (2023-2025)
- Hypertet $1,230 associated (2023-2025)
- Alphanate $117 associated (2023-2025)
- Albutein $84.78 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Stephen Scholand | Meriden, CT | Infectious Disease | $365,185.02 |
| Fredrick Melik-Abrahamian | Sylmar, CA | Emergency Medicine | $258,481.84 |
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $247,073.57 |
| Bob Geng | San Diego, CA | Allergy & Immunology | $214,225.49 |
| Antoine Azar | Baltimore, MD | Allergy & Immunology (Internal Medicine) | $214,072.56 |
| Richard Wasserman | Dallas, TX | Allergy & Immunology | $177,086.50 |
| Gil Wolfe | Buffalo, NY | Neurology (Psychiatry & Neurology) | $175,550.63 |
| Suraj Muley | Phoenix, AZ | Neurology (Psychiatry & Neurology) | $152,530.17 |
| David Mares | Anderson, IN | Pulmonary Disease | $149,554.92 |
| Manish Butte | Los Angeles, CA | Pediatric Allergy/Immunology | $149,104.32 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.